

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Assistant Commissioner for Patents  
Washington, D.C. 20231

Atty. Dkt.: 1430-272

Date: August 29, 2001

11017 U.S. PTO  
09/940422  
08/29/01

Attached for filing is the patent application of:

Inventor: EDMEADES et al

Title: COMPOUND AND ITS USE

including attachments as noted below:

- ☐ Newly executed Declaration, ☒ Copy of Declaration from prior application, ☐ Abstract  
26 pages of specification and claims (including 4 numbered claims), and  
0 sheets of accompanying drawing/s.  
☐ Record the attached assignment and return to the undersigned.  
☐ Attached is a Power of Attorney.  
☒ Priority is hereby claimed under 35 U.S.C. § 119 based on the following foreign applications:

**Application Number**  
9812413.4

**Country**  
Great Britain

**Day/Month/Year Filed**  
10 June 1998

, respectively, the entire content of which is hereby incorporated by reference in this application..

Certified copy(ies) of foreign application(s) is/are attached.

Certified copy(ies) filed on March 10, 1999 in prior appln. no. 09/265,670 filed March 10, 1999

☒ Please amend the specification by inserting the following paragraph before the first line: --This application is a division of Application No. 09/265,670, filed March 10, 1999, , the entire content of which is hereby incorporated by reference in this application.--

Petition filed in prior application to extend its life to insure co-pendency.

The prior application is assigned to Glaxo Wellcome Inc..

It is hereby requested that the Examiner consider the art cited in the parent application by applicant and/or the Examiner for the reasons stated therein. A listing of that art is attached.

Applicant claims "small entity" status. ☐ "Small entity" statement attached.

Please enter the attached and/or below preliminary amendment prior to calculation of filing fee:

**Cancel claims 2-11. Preliminary Amendment attached.**

Also attached: ☐ Information Disclosure Statement; ☐ Non-Publication Request; ☐ Nucleotide and/or Amino Acid Sequence Submission; ☐ Statement deleting Inventor(s) named in prior application; ☐ Other:

**FILING FEE IS BASED ON CLAIMS AS FILED LESS ANY HERewith CANCELED**

Basic Filing Fee			\$	710.00
Total effective claims	4	- 20 (at least 20) =	0 x \$ 18.00	\$ 0.00
Independent claims	2	- 3 (at least 3) =	0 x \$ 80.00	\$ 0.00
If any proper multiple dependent claims now added for first time, add \$270.00 (ignore improper)				\$ 0.00
			<b>SUBTOTAL</b>	\$ 710.00
If "small entity," then enter half (1/2) of subtotal and subtract			-\$	(0.00)
			<b>SECOND SUBTOTAL</b>	\$ 710.00
Assignment Recording Fee (\$40.00)				\$ 0.00
			<b>TOTAL FEE ENCLOSED</b>	\$ 710.00

Any future submission requiring an extension of time is hereby stated to include a petition for such time extension.

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our **Account No. 14-1140**. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
ARC:pfc

**NIXON & VANDERHYE P.C.**

By Atty: Arthur R. Crawford, Reg. No. 25,327

Signature: \_\_\_\_\_